Pemetrexed-carboplatin salvage therapy in advanced thyroid cancers.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: advanced thyroid cancers that have progressed following targeted therapies is limited, indicating a strong need for salvage treatments
I · Intervention 중재 / 시술
novel salvage PC
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
On this fourth line treatment, the patient remains on therapy to date, over 12 months after initial response. [CONCLUSIONS] This case series reinforces prior published phase I clinical trial data and shows that pemetrexed can have potent efficacy in the treatment of the most advanced thyroid cancers.
[BACKGROUND] The overall survival of patients with advanced thyroid cancers that have progressed following targeted therapies is limited, indicating a strong need for salvage treatments.
- 표본수 (n) 7
APA
Lee KK, Morris JC, et al. (2025). Pemetrexed-carboplatin salvage therapy in advanced thyroid cancers.. Head & neck, 47(3), 813-821. https://doi.org/10.1002/hed.27940
MLA
Lee KK, et al.. "Pemetrexed-carboplatin salvage therapy in advanced thyroid cancers.." Head & neck, vol. 47, no. 3, 2025, pp. 813-821.
PMID
39462887 ↗
Abstract 한글 요약
[BACKGROUND] The overall survival of patients with advanced thyroid cancers that have progressed following targeted therapies is limited, indicating a strong need for salvage treatments.
[METHODS] We retrospectively analyzed patients with refractory advanced thyroid cancer treated with pemetrexed-carboplatin (PC) at Mayo Clinic since 2019.
[RESULTS] Eleven patients, three with anaplastic thyroid cancer (ATC), seven with differentiated or poorly differentiated thyroid cancer (DTC), and one with oncocytic carcinoma of the thyroid, were treated with novel salvage PC. Patients with DTC (n = 7) had durable responses with a median progression-free survival of 29 months. One responder included a patient with ATC whose disease progressed following pembrolizumab/axitinib, lenvatinib, and dabrafenib/trametinib. On this fourth line treatment, the patient remains on therapy to date, over 12 months after initial response.
[CONCLUSIONS] This case series reinforces prior published phase I clinical trial data and shows that pemetrexed can have potent efficacy in the treatment of the most advanced thyroid cancers.
[METHODS] We retrospectively analyzed patients with refractory advanced thyroid cancer treated with pemetrexed-carboplatin (PC) at Mayo Clinic since 2019.
[RESULTS] Eleven patients, three with anaplastic thyroid cancer (ATC), seven with differentiated or poorly differentiated thyroid cancer (DTC), and one with oncocytic carcinoma of the thyroid, were treated with novel salvage PC. Patients with DTC (n = 7) had durable responses with a median progression-free survival of 29 months. One responder included a patient with ATC whose disease progressed following pembrolizumab/axitinib, lenvatinib, and dabrafenib/trametinib. On this fourth line treatment, the patient remains on therapy to date, over 12 months after initial response.
[CONCLUSIONS] This case series reinforces prior published phase I clinical trial data and shows that pemetrexed can have potent efficacy in the treatment of the most advanced thyroid cancers.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Thyroid Neoplasms
- Pemetrexed
- Male
- Female
- Retrospective Studies
- Middle Aged
- Salvage Therapy
- Aged
- Carboplatin
- Antineoplastic Combined Chemotherapy Protocols
- Thyroid Carcinoma
- Anaplastic
- 80 and over
- Adult
- Treatment Outcome
- advanced thyroid cancer
- anaplastic
- poorly differentiated
- radioactive iodine refractory
- salvage
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.